Aroma E-Juice: Legit Or A Scam?

Aroma Ejuice LLC was issued a warning letter by the U.S. Food and Drug Administration (FDA) in 2019 for selling e-liquid products that were deemed to be misbranded and in violation of federal tobacco regulations. The company was found to have sold e-liquid products to minors and failed to include the required nicotine warning statements on their product labels and advertising. As a result, the FDA requested that Aroma Ejuice LLC take immediate corrective actions to ensure compliance with the Federal Food, Drug, and Cosmetic Act (FD&C Act) to prevent further regulatory actions.

Aroma Ejuice's Beatle Juice e-liquid is misbranded and sold to minors

The U.S. Food and Drug Administration (FDA) has determined that Aroma Ejuices LLC's Beatle Juice e-liquid product is misbranded and sold to minors. The FDA's investigation revealed that the product was sold to a person under the age of 18, which is a violation of federal law. In addition, the labeling and advertising for the product do not include the required nicotine warning statement, which also constitutes misbranding. The company was issued a warning letter by the FDA, which requested that the company take immediate corrective action to bring its tobacco products into compliance with the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The FDA's warning letter outlines several violations committed by Aroma Ejuices LLC, including the sale of e-liquid to a minor and the failure to include the required nicotine warning statement on its mobile website and product labeling. The company was given 15 working days to respond to the warning letter and provide a plan for correcting the violations. Failure to comply with the FD&C Act may result in further action from the FDA, including civil penalties, no-tobacco-sale orders, criminal prosecution, seizure, and/or injunction.

The consequences of non-compliance with the FD&C Act are outlined in detail, and the company is urged to take immediate action to correct the violations and ensure full compliance with the law. The warning letter emphasizes the responsibility of the company to ensure that all its tobacco products, labeling, advertising, and websites comply with the applicable provisions of the FD&C Act and FDA's implementing regulations.

Aroma Ejuice's website fails to include the required nicotine warning

The U.S. Food and Drug Administration (FDA) recently reviewed the Aroma Ejuice LLC mobile website and determined that the e-liquid products listed there are manufactured and offered for sale or distribution within the United States. The FDA has determined that several e-liquid products advertised and offered for sale or distribution on the mobile website are misbranded, as they fail to include the required nicotine warning statement.

The nicotine warning statement required by the FDA for e-liquid products is as follows:

> WARNING: This product contains nicotine. Nicotine is an addictive chemical.

The absence of this warning statement on the mobile website regarding e-liquid products is a violation of section 903(a)(7)(B) of the FD&C Act (21 U.S.C. § 387c(a)(7)(B)), section 903(a)(1) of the FD&C Act (21 U.S.C. § 387c(a)(1)), and/or section 903(a)(7)(A) of the FD&C Act (21 U.S.C. § 387c(a)(7)(A)). The failure to include the required nicotine warning statement may result in further action from the FDA, including civil money penalties, no-tobacco-sale orders, criminal prosecution, seizure, and/or injunction.

Aroma Ejuice LLC was requested to submit a written response within 15 working days, outlining their corrective actions and plan for maintaining compliance with the FD&C Act.

Aroma Ejuice's products are tobacco-derived

Aroma Ejuices products are tobacco-derived. In 2019, the U.S. Food and Drug Administration (FDA) reviewed the mobile website http://www.aromaejuice.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.

Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Family Smoking Prevention and Tobacco Control Act, these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&C Act.

The FDA has determined that several e-liquid products advertised and offered for sale or distribution on the Aroma Ejuice mobile website are misbranded under various sections of the FD&C Act. The website regarding e-liquid products fails to include the required nicotine warning statement for these e-liquid products.

A tobacco product is misbranded under section 903(a)(1) of the FD&C Act if its labelling is false or misleading in any particular. Under section 201(n) of the FD&C Act, in determining whether labelling and/or advertising is misleading, the agency considers the failure to reveal material facts concerning the consequences that may result from the customary or usual use of the product.

Aroma Ejuice was requested to submit a written response within 15 working days, describing their corrective actions and plan for maintaining compliance with the FD&C Act.

Aroma Ejuice's products are subject to FDA jurisdiction

Aroma Ejuices products are subject to FDA jurisdiction. The U.S. Food and Drug Administration (FDA) has the authority to regulate tobacco products, including e-liquids, under the Federal Food, Drug, and Cosmetic Act (FD&C Act). This means that Aroma Ejuices must comply with the regulations set by the FDA to ensure that their products are safe for human consumption.

The FDA's Center for Tobacco Products is responsible for regulating e-cigarettes, vapes, and other Electronic Nicotine Delivery Systems (ENDS). This includes the regulation of e-liquids, which are liquids used in electronic cigarettes and vapes. The FDA has the power to inspect and take enforcement actions against manufacturers and retailers of e-liquids to ensure that they meet the required safety and labelling standards.

In the case of Aroma-Company, the FDA has determined that their products are subject to FDA jurisdiction and has issued a warning letter outlining a misbranding violation. The violation relates to the labelling and advertising of their Candy King Batch e-liquid, which imitates the labelling and advertising of candy that is marketed towards children. The FDA has requested that Aroma-Company take corrective actions to bring their products into compliance with the FD&C Act.

It is important for consumers to be aware of the regulations surrounding e-liquids and to only purchase products that comply with FDA standards. While the use of e-cigarettes and vapes may be a popular alternative to traditional cigarettes, it is crucial to ensure that the products are safe and properly labelled to reduce potential health risks.

Aroma Ejuice's products are misbranded under the FD&C Act

The U.S. Food and Drug Administration (FDA) has determined that several of Aroma Ejuice LLC's products are misbranded under the Federal Food, Drug, and Cosmetic (FD&C) Act. This determination was made after a review of the company's mobile website, which revealed that certain e-liquid products were sold to minors and did not include the required nicotine warning statement.

The FDA's investigation found that Aroma Ejuice LLC sold their Beatle Juice e-liquid product to a person under the age of 18, which is prohibited by federal regulations. The company's mobile website also failed to include the required nicotine warning statement for several e-liquid products, including Beatle Juice, RY 4, Sahara, Darjim Black Clove, DK TAB, Flue Cured Tobacco, Newbie, PM, Turkish Blend, and Virginia Blend. The absence of this warning statement is a violation of the FD&C Act and results in these products being misbranded.

In addition, the FDA has provided a conclusion and requested actions for Aroma Ejuice LLC to correct these violations and ensure full compliance with the FD&C Act. The company is responsible for ensuring that their tobacco products, labeling, advertising, and websites comply with the applicable provisions. Failure to do so can result in further action from the FDA, including civil penalties, criminal prosecution, seizure, and injunction.

Frequently asked questions